ArticleOncoimmunology
Immunotherapy with Listeria reduces metastatic breast cancer in young and old mice through different mechanisms.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 34 citations in OpenAlex.
- Oral immunization withJournal for immunotherapy of cancer · 2026Article
- Intratumoral microbiota and metabolites: dual roles in cancer progression and therapeutic opportunities.Cell communication and signaling : CCS · 2026Review
- Intratumoral Microbiome-Tumor Microenvironment Crosstalk in Breast Cancer Aggressiveness.The breast journal · 2026Review
- Engineering bacteria for enhanced tumor therapy: from surface modification to synthetic genetic circuits.Journal of hematology & oncology · 2025Review
- Effects of aging on anticancer therapy in murine cancer models.Cancer metastasis reviews · 2025Review
- Intratumoural microbiota: from theory to clinical application.Cell communication and signaling : CCS · 2023Review
- Listeria-based vaccination against the pericyte antigen RGS5 elicits anti-vascular effects and colon cancer protection.Oncoimmunology · 2023Article
- Bacterial immunotherapy: is it a weapon in our arsenal in the fight against cancer?Frontiers in immunology · 2023Review
- Molecular Characterization of CF33 Canine Cell Line and Evaluation of Its Ability to Respond against Infective Stressors in Sight of Anticancer Approaches.Veterinary sciences · 2022Article
- Article
- Clinical Experience and Recent Advances in the Development ofFrontiers in immunology · 2021Review
- Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice.Journal for immunotherapy of cancer · 2020Article
- Tumour-targeting bacteria engineered to fight cancer.Nature reviews. Cancer · 2018Review
- White paper on microbial anti-cancer therapy and prevention.Journal for immunotherapy of cancer · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Cancer immunotherapy is one of the most promising and benign therapies against metastatic cancer. However, most cancer patients are old and elderly react less efficient to cancer vaccines than young adults, due to T cell unresponsiveness. Here we present data of cancer vaccination in young and old mice with metastatic breast cancer (4T1 model). We tested adaptive and innate immune responses to foreign antigens (Listeria-derived) and self-antigens (tumor-associated antigens (TAA)) and their contribution to elimination of metastases at young and old age. Three different protocols were tested with Listeria: a semi- and exclusive-therapeutic protocol both one-week apart, and an exclusive therapeutic protocol frequently administered. Adaptive and innate immune responses were measured by ELISPOT in correlation with efficacy in the 4T1 model. We found that Listeria induced immunogenic tumor cell death, resulting in CD8 T cell responses to multiple TAA expressed by the 4T1 tumors. Only exclusive therapeutic frequent immunizations were able to overcome immune suppression and to activate TAA- and Listeria-specific CD8 T cells, in correlation with a strong reduction in metastases at both ages. However, MHC class Ia antibodies showed inhibition of CD8 T cell responses to TAA at young but not at old age, and CD8 T cell depletions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.